keyboard_arrow_up

Peripheral Neuropathy (Sensory Neuropathy) Pipeline Review and Market Updates, H2 2015

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and special features on late-stage and discontinued projects.

Get a copy of this report at http://bit.ly/1IXY9OZ . This is a premium report price at US$2000 for a single user PDF license

Companies Mentioned in report are Arcturus Therapeutics, Inc, aTyr Pharma, Inc., GeNeuro SA, INSYS Therapeutics, Inc., Mitsubishi Tanabe Pharma Corporation, Neuren Pharmaceuticals Limited, Pfizer Inc., Polyneuron Pharmaceuticals AG,
RegeneRx Biopharmaceuticals, Inc., Teijin Pharma Limited

Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Scope

- The report reviews key players involved in the therapeutics development for Peripheral Neuropathy (Sensory Neuropathy) and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects

- A review of the Peripheral Neuropathy (Sensory Neuropathy) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Peripheral Neuropathy (Sensory Neuropathy) pipeline on the basis of target, MoA, route of administration and molecule type

The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.